Sun spots and age spots (solar lentigines): what actually fades them

Sun spots, age spots, liver spots — clinically, solar lentigines — are flat, well-defined patches of localized dark pigment that appear on sun-exposed skin: the backs of the hands, the face, the shoulders and upper chest, the forearms. They are extremely common, especially after 50, and they are benign. They are also one of the most common reasons people seek aesthetic treatment, because they read as visible aging in a way that even skin texture does not.

The good news is that true solar lentigines respond well to treatment — better than almost any other pigment problem, including melasma. The catch is two-fold: a changing or irregular dark lesion must be evaluated for melanoma before any cosmetic treatment, and the choice of treatment has to respect your skin type, because the wrong device on the wrong skin causes post-inflammatory hyperpigmentation (PIH) that can be harder to fade than the original spot. This article lays out the evidence ladder — sunscreen, prescription topicals, cryotherapy, chemical peels, IPL, and pigment lasers — with the comparative efficacy data and the Fitzpatrick considerations that change the plan. It is educational and not a substitute for care from a board-certified dermatologist.

The safety gate: rule out lentigo maligna first

Every dark spot is not a sun spot. Lentigo maligna is an in-situ melanoma that arises in chronically sun-damaged skin and can look, to a patient, exactly like a solar lentigo — a flat, enlarging, pigmented patch on the face of an older adult. Treating a lentigo maligna cosmetically — with a laser, a peel, or a freezing session — can destroy the visible pigment while leaving malignant cells behind, delaying diagnosis of a cancer that can become invasive and life-threatening.

This is why the first step for any new, changing, growing, irregularly colored, or oddly bordered lesion is a dermatologic evaluation, not a laser appointment. The ABCDE rule applies: Asymmetry, irregular Borders, multiple Colors, large Diameter (over ~6 mm), and Evolution (change over time). A lesion that fails any of those — or that simply looks different from the patient's other spots (the "ugly duckling" sign) — needs dermoscopy and, when indicated, a biopsy before any cosmetic treatment is considered. Once a spot is confirmed to be a benign solar lentigo, the treatment ladder below applies.

What solar lentigines are and why they form

A solar lentigo is a localized proliferation of melanocytes — the pigment-producing cells — with clumping of melanin within the epidermis, driven by cumulative ultraviolet exposure. Unlike a tan (even pigment across sun-exposed skin) or freckles (ephelides, which darken in summer and fade in winter), a solar lentigo is a fixed structural change that does not fade on its own. It is a marker of chronic photoaging: the same UV exposure that produces it also drives the broader signs of sun damage — fine lines, texture, broken capillaries — which is why lentigines are often treated as part of an overall photorejuvenation plan.

The foundation: sun protection

No treatment works for long without it. UV exposure both causes new lentigines and drives re-pigmentation of treated ones, so daily, broad-spectrum, SPF 30+ sun protection is the single most effective long-term measure — for prevention, for protecting the results of an in-office treatment, and for keeping topical regimens effective. Patients who pay for a picosecond laser course and then skip sunscreen watch the spots return. Sun protection is not optional filler; it is the backbone of the entire strategy.

Evidence-based topicals

Topicals are the slow, low-risk, lower-cost end of the ladder. They work over months, not weeks, and they are best for patients who want gradual improvement, who have many small spots, or whose skin type makes device treatment riskier. The options, in rough order of evidence:

• Hydroquinone is the gold-standard tyrosinase inhibitor (it blocks the enzyme that makes melanin). It is effective but comes with rules: it is cycling-only (typically used for ~3 months then rested) to avoid a paradoxical bluish-gray darkening called exogenous ochronosis with long-term overuse. In the US, OTC hydroquinone was classified Category II (not generally recognized as safe and effective) under the 2020 CARES Act OTC monograph reform that finalized FDA's long-standing 2006 proposal — so since September 2020 hydroquinone is no longer sold over the counter and is dispensed by prescription.
• Mequinol 2% + tretinoin 0.01% (the combination in Solage) has the strongest topical evidence in the recent systematic review — efficacy in the 52.6% to over 80% range, especially for facial lesions.
• Tretinoin and other retinoids increase cell turnover and are often combined with a tyrosinase inhibitor.
• Azelaic acid, vitamin C (ascorbic acid), niacinamide, kojic acid, licorice root extract, and cysteamine are supportive tyrosinase inhibitors and antioxidants with varying evidence; they are gentler and useful for maintenance and for patients who cannot tolerate hydroquinone.

In-office treatments — and the comparative efficacy

A 2025 systematic review of clinical trials for solar lentigines (Mardani et al., Journal of Cosmetic Dermatology) gives the clearest comparative picture in years. The headline finding is that lasers outperform other modalities, and combining a laser with a topical agent further improves results and reduces PIH. Reported efficacy ranges from the review:

• Picosecond lasers: 67.9%–93.0% — the most effective single device category, delivering pigment clearance with ultra-short pulses that shatter melanin with less surrounding heat (and thus lower PIH risk).
• Intense pulsed light (IPL/BBL): 74.6%–90% — strong efficacy, and because IPL treats a broad field, it doubles as overall photorejuvenation for diffuse sun damage; best in lighter skin and for many small spots.
• Q-switched lasers (532 nm KTP / Nd:YAG): 36.4%–76.6% — the long-standing mainstay pigment laser; the 532 nm KTP is the classic choice for epidermal lentigines.
• Pulsed dye laser: 27%–57% — moderate; PDL targets vessels more than pigment, so it is not the natural fit but can help spots with a vascular component.
• Fractional CO₂ laser: only 8%–23% — surprisingly weak for pure pigment; fractional resurfacing remodels texture but is not an efficient lentigo treatment.
• Cryotherapy (liquid nitrogen): a consensus first-line for isolated lesions — fast, cheap, and effective — but it carries meaningful PIH risk in darker skin, which is why many dermatologists avoid or modify it for Fitzpatrick IV–VI.
• Chemical peels (glycolic acid, salicylic acid, TCA, Jessner's): effective supporting options, especially for diffuse pigmentation and for darker skin where pigment and peeling are better tolerated than high-energy light devices.

The practical logic: isolated spots → cryotherapy or Q-switched/pico laser; diffuse sun damage with many spots → IPL or a chemical peel; single high-value lesion on the face → picosecond laser for the best clearance-to-PIH ratio. Always layer a tyrosinase-inhibitor topical and strict sun protection on top.

Skin-of-color considerations

In Fitzpatrick IV–VI, the dominant risk across all light-based lentigo treatments is post-inflammatory hyperpigmentation — the treatment inflames the skin, melanin floods in, and the patient is left with a dark patch that can persist for months and may be harder to treat than the original lentigo. The plan shifts accordingly: lower energy, conservative test spots, longer intervals, and a relative preference for chemical peels, topical regimens, and picosecond lasers at low settings over high-energy IPL or aggressive cryotherapy. Many practitioners pre-treat darker skin with a tyrosinase inhibitor for several weeks before a laser session to prime the skin and reduce PIH, and strict sun protection before and after is mandatory. Any device plan in skin of color should be built around pigment safety first.

A practical treatment-by-situation table

Realistic outcomes and what to expect

True solar lentigines are among the most reliably treatable pigment concerns — a single picosecond or IPL session can produce dramatic lightening, and a short course often achieves near-clearance for epidermal spots. The limits are three: deeper (dermal) pigment responds less than superficial pigment; treated spots can recur with continued UV exposure (hence the sunscreen emphasis); and in darker skin the PIH risk can dominate the outcome. The patients most satisfied are those whose spots were confirmed benign, whose treatment matched their skin type, and who treated the spots as part of an ongoing photoprotection plan rather than a one-time fix.

What it costs

Lentigo treatment is cosmetic and is not covered by insurance. Cryotherapy is the cheapest option (often a low per-lesion fee). Chemical peels run roughly $150–$400 per session. IPL/BBL and pigment lasers typically fall in the $300–$700 per-session range, with a single spot sometimes treatable in one session and diffuse photodamage needing a course of two to four. Because results for isolated spots can be quick while diffuse damage needs a course, the total can range from a few hundred dollars to the low thousands. The number to compare is the all-in cost for the planned course and any maintenance.

What to ask a provider

• Has this spot been examined and confirmed benign? A credible answer involves dermoscopy, not just a glance.
• For my skin type, which device carries the lowest PIH risk? A good answer names topical/pico/peel options for darker skin.
• Is this a single-session lesion or a course, and what total cost and improvement should I expect?
• Will I pre-treat with a tyrosinase inhibitor, and what is my sun-protection plan? If sunscreen is not central to the plan, that is a flag.
• If I have many spots plus overall sun damage, are we treating the field (IPL/peel) or spot-by-spot? The answer should fit the pattern of your pigmentation.

Sun spots are benign, common, and — once melanoma is ruled out — among the most rewarding pigment problems to treat. The treatment that works is the one matched to the lesion, the skin type, and a serious sun-protection plan. A provider who skips the skin check, the sunscreen, or the Fitzpatrick conversation is not the one to perform it.

Sources

• Journal of Cosmetic Dermatology — Treatment of Solar Lentigines: A Systematic Review of Clinical Trials (Mardani et al., 2025; pico 67.9–93%, IPL 74.6–90%, Q-switched 36.4–76.6%, PDL 27–57%, fractional CO₂ 8–23%, mequinol/tretinoin 52.6–80%): https://pmc.ncbi.nlm.nih.gov/articles/PMC11948172
• Dermatology Times — Laser and Topical Treatments for Solar Lentigines (532 nm KTP mainstay, combination approach): https://www.dermatologytimes.com/view/sun-spots-cutting-edge-treatment-solar-lentigines-uses-combination-approach
• FDA — Rulemaking History for OTC Skin Bleaching Drug Products (hydroquinone classification and prescription status): https://www.fda.gov/drugs/historical-status-otc-rulemakings/rulemaking-history-otc-skin-bleaching-drug-products
• AAD — Age spots / sun spots overview and sun protection guidance: https://www.aad.org/public/everyday-skin-care/looks/age-spots
• Medscape / eMedicine — Lentigines Treatment & Management (cryotherapy first-line, peels, lasers): https://emedicine.medscape.com/article/1067321-treatment
• American Society for Dermatologic Surgery (ASDS) — Skin concerns and treatment information (sun spots, lasers, peels): https://asds.net/skin-experts/skin-treatments